Skip to main navigation Skip to search Skip to main content

ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer

  • Qiang Li
  • , Alexis W. Damish
  • , Zoë Frazier
  • , David Liu
  • , Elizaveta Reznichenko
  • , Atanas Kamburov
  • , Andrew Bell
  • , Huiyong Zhao
  • , Emmet J. Jordan
  • , Sizhi P. Gao
  • , Jennifer Ma
  • , Philip Abbosh
  • , Joaquim Bellmunt
  • , Elizabeth R. Plimack
  • , Jean Bernard Lazaro
  • , David B. Solit
  • , Dean Bajorin
  • , Jonathan E. Rosenberg
  • , Alan D. D'Andrea
  • , Nadeem Riaz
    • Eliezer M. Van Allen, Gopa Iyer
  • Memorial Sloan-Kettering Cancer Center
  • Roswell Park Cancer Institute
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Massachusetts Institute of Technology
  • Massachusetts General Hospital
  • Bayer AG
  • Cornell University
  • Harvard University
  • Broad Institute
  • University of British Columbia
  • University of Toronto
  • University of Edinburgh
  • Hospital del Mar
  • Beth Israel Deaconess Medical Center
  • Thomas Jefferson University
  • Einstein Healthcare Network
  • Boston Children's Hospital

Research output: Contribution to journal › Article › peer-review

144 Scopus citations

Fingerprint

Dive into the research topics of 'ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer'. Together they form a unique fingerprint.
Sort by

Biochemistry, Genetics and Molecular Biology